Treatment of diabetes with milk protein hydrolysate
AssigneeNestec S.A.
InventorsRaylene Reimer, Christian Darimont-Nicolau, Katherine Mace, Sandrine Gremlich, Jean-Richard Neeser
Life of this patent
Estimating the term…
Abstract
A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.
Claims2
A method for assessing proglucagon gene expression and GLP-1 release by human cells which comprises:
- obtaining a cell line derived from an adenocarcinoma of human caecum, wherein the cell line is a NCI-H716 cell line having the ATCC number CCL-251;
- treating the cell line with a composition comprising a milk protein hydrolysate;
- and
- measuring the amount of GLP-1 secreted by the cell line.
Dependencies are inferred from the claim text.